Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pilar Mediavilla-Medel
Observed names:
P. Mediavilla Medel,
P. Mediavilla-Medel,
Pilar Mediavilla,
Pilar Mediavilla Medel,
Pilar Mediavilla Medel*
Institutions:
Universidad Complutense de Madrid,
Hospital Universitario Puerta de Hierro Majadahonda
Observed institutions:
Universidad Complutense de Madrid,
Consejo Superior de Investigaciones Científicas,
Centro Nacional de Biotecnología,
Hospital Universitario Puerta de Hierro Majadahonda
ORCID:
0000-0001-9076-4415
Observed ORCID:
0000-0001-9076-4415
OpenAlex ID:
A5033639242
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
·
Clinical Cancer Research
·
20
PDF
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
2025
·
Mariano Provencio
, Begoña Campos
, et al.
·
Nature Communications
·
20
PDF
A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
2019
·
Beatriz Perdiguero
, Cristina Sánchez-Corzo
, et al.
·
Viruses
·
19
PDF
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study
2025
·
Roberto Serna Blasco*
, Pilar Mediavilla Medel*
, et al.
·
Lung Cancer
·
12
Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
2019
·
Beatriz Perdiguero
, Cristina Sánchez-Corzo
, et al.
·
Vaccines
·
8
PDF
Optimizing genetic testing strategy for suspected attenuated adenomatous polyposis: effective solutions in public health systems
2024
·
Natalia García-Simón
, Fátima Valentín
, et al.
·
Clinical & Translational Oncology
·
4
PDF
Liquid Biopsy in Advanced Prostate Cancer
2026
·
Pilar Mediavilla-Medel
, Natalia García-Simón
, et al.
·
Cancers
·
3
PDF
Abstract 6684: Impact of fecal microbiome on the efficacy of neoadjuvant chemo-immunotherapy and colitis adverse events: Findings from the NADIM II Trial
2024
·
Roberto Serna-Blasco
, Alejandro Rodriguez Festa
, et al.
·
Cancer Research
·
3
MA01.03 Metabolomic Analysis Identifies Histamine as a Key Predictive Factor for Perioperative Chemoimmunotherapy in NADIM II Trial
2025
·
P. Mediavilla-Medel
, E. Nadal
, et al.
·
Journal of Thoracic Oncology
·
1
1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib
2024
·
L. Robado de Lope
, M.R. García Campelo
, et al.
·
Annals of Oncology
·
1
Analytical and Clinical Validation of a Focused ctDNA Genomic Profiling Panel for Advanced Non-small Cell Lung Cancer
2026
·
Pilar Mediavilla Medel
, Roberto Serna-Blasco
, et al.
·
The Journal of Liquid Biopsy
PDF
Validation of a ctDNA-Based comprehensive genomic profiling panel (IST80 Plus) for advanced non-small cell lung cancer
2026
·
Pilar Mediavilla-Medel
, Roberto Serna-Blasco
, et al.
·
The Journal of Liquid Biopsy
PDF
Supplementary Table S1 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Supplementary Figure S3 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Supplementary Figure S4 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Supplementary Figure S2 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Supplementary Data S1 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Supplementary Figure S1 from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Data from Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
2026
·
Mariano Provencio
, Roberto Serna-Blasco
, et al.
Show more works
View as search
Works count:
19
Citation count:
91
H-index:
5
I10-index:
4
Year
Topic
Type